ClinicalTrials.gg
CompletedNCT00141323PEARLUpdated Aug 15, 2011

Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)

A Phase 3 interventional study of lasofoxifene and placebo in Osteoporosis, sponsored by Ligand Pharmaceuticals. Completed at 201 sites in 32 countries. Open to female participants aged 60 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-08-15.

Sponsored by Ligand Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
8,556
Allocation
Randomized
Ages
60 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 481 studies in Osteoporosis with a site in United States — 26 open to participants now, 36 under way, none of them phase 3. Osteoporosis · United States.

Planned enrollment
3rd of 374
8,556 · median 73
Started
2001
with 18 others
Phase 3
70 of 481
none open now
Registered
88th of 481
by date

Among the 481 studies in Osteoporosis with a site in United States, this one is the 3rd largest by planned enrollment of the 374 interventional ones that give a count, is one of 19 that started in 2001, is one of 70 in phase 3, and was the 88th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

26 of the 481 studies in Osteoporosis with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 60 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 481 studies in Osteoporosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to determine the safety and effectiveness of 2 doses of the investigational drug, lasofoxifene, compared to placebo (an inactive substance) in reducing new spinal fractures in women with osteoporosis.

03

Conditions studied

  • Osteoporosis

Browse trials for

04

Who can participate

Ages eligible
60 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

at least 5 years; Screening bone mineral density more than or equal to 2.5 S.D.s below the mean for young adults at the lumbar spine or femoral neck.

Exclusion criteria

Exclusion Criteria:

Metabolic bone disease other than osteoporosis; Taking approved medications for osteoporosis; Have had a recent osteoporotic fracture (within 1 year) and/or have a bone mineral density more than 4.5 S.D.s below the mean for young adults at the lumbar spine or femoral neck.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
8,556 participants (estimated)

Study arms

  • Experimental
    lasofoxifene 0.5 mg/day

    Drug: lasofoxifene

  • Placebo comparator
    placebo

    Other: placebo

  • Experimental
    lasofoxifene 0.25 mg/day

    Drug: lasofoxifene

Interventions

06

What researchers measure

Primary outcomes

  1. New morphometric vertebral fractures

    Time frame: 3 years

  2. New cases of breast cancer

    Time frame: 5 years

  3. New non-vertebral fractures

    Time frame: 5 years

Secondary outcomes

  1. All clinical fractures, non-vertebral fractures, BMD, breast cancer, cardiovascular events, and gynecological safety events

    Time frame: 3 years

  2. All clinical fractures, new morphometric vertebral fractures, BMD, cardiovascular events, and gynecological safety events

    Time frame: 5 years

07

Study locations

201 sites
  • Pfizer Investigational Site
    Birmingham, Alabama 35205, United States
  • Pfizer Investigational Site
    Birmingham, Alabama 35216, United States
  • Pfizer Investigational Site
    La Jolla, California 92037, United States
  • Pfizer Investigational Site
    La Jolla, California 92093-0659, United States
  • Pfizer Investigational Site
    La Jolla, California 92161, United States
  • Pfizer Investigational Site
    Palm Desert, California 92260, United States
  • Pfizer Investigational Site
    Palm Springs, California 92262, United States
  • Pfizer Investigational Site
    Palm Springs, California 92263, United States
  • Pfizer Investigational Site
    Poway, California 94064, United States
  • Pfizer Investigational Site
    Rancho Mirage, California 92270, United States
  • Pfizer Investigational Site
    San Diego, California 92123, United States
  • Pfizer Investigational Site
    San Diego, California 92128, United States
  • Pfizer Investigational Site
    Brandon, Florida 33611, United States
  • Pfizer Investigational Site
    Leesburg, Florida 34748, United States
  • Pfizer Investigational Site
    Tampa, Florida 33607, United States
  • Pfizer Investigational Site
    Tampa, Florida 33613, United States
  • Pfizer Investigational Site
    Tampa, Florida 33614, United States
  • Pfizer Investigational Site
    West Palm Beach, Florida 33414, United States
  • Pfizer Investigational Site
    Des Plaines, Illinois 60016, United States
  • Pfizer Investigational Site
    Morton Grove, Illinois 60053, United States
  • Pfizer Investigational Site
    Des Moines, Iowa 50309, United States
  • Pfizer Investigational Site
    Bethesda, Maryland 20817, United States
  • Pfizer Investigational Site
    Montgomery Village, Maryland 20886, United States
  • Pfizer Investigational Site
    Arden Hills, Minnesota 55112, United States
  • Pfizer Investigational Site
    Minneapolis, Minnesota 55415-1226, United States
  • Pfizer Investigational Site
    Omaha, Nebraska 68131, United States
  • Pfizer Investigational Site
    Albuquerque, New Mexico 87102, United States
  • Pfizer Investigational Site
    Albuquerque, New Mexico 87106, United States
  • Pfizer Investigational Site
    Centerville, Ohio 45459, United States
  • Pfizer Investigational Site
    Dayton, Ohio 45409, United States
  • Pfizer Investigational Site
    Portland, Oregon 97239, United States
  • Pfizer Investigational Site
    Charleroia, Pennsylvania 15022, United States
  • Pfizer Investigational Site
    Monessen, Pennsylvania 15062, United States
  • Pfizer Investigational Site
    Cordova, Tennessee 38018, United States
  • Pfizer Investigational Site
    Memphis, Tennessee 38119, United States
  • Pfizer Investigational Site
    Dallas, Texas 75230, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78229, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23225, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23227, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23229, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23235, United States
  • Pfizer Investigational Site
    Redmond, Washington 98052, United States
  • Pfizer Investigational Site
    Seattle, Washington 98101-1448, United States
  • Pfizer Investigational Site
    Seattle, Washington 98104, United States
  • Pfizer Investigational Site
    Seattle, Washington 98105-4631, United States
  • Pfizer Investigational Site
    Seattle, Washington 98112, United States
  • Pfizer Investigational Site
    Seattle, Washington 98133, United States
  • Pfizer Investigational Site
    Seattle, Washington 98195, United States
  • Pfizer Investigational Site
    Capital Federal, Buenos Aires C1114AAH, Argentina
  • Pfizer Investigational Site
    Capital Federal, Buenos Aires C1117ABH, Argentina
  • Pfizer Investigational Site
    Buenos Aires, Capital Federal C1287ACF, Argentina
  • Pfizer Investigational Site
    Rosario, Santa Fe S2000 DHL, Argentina
  • Pfizer Investigational Site
    Rosario, Santa Fe S2000DHL, Argentina
  • Pfizer Investigational Site
    Capital Federal - Buenos Aires, C1012AAP, Argentina
  • Pfizer Investigational Site
    Capital Federal, C1115AAJ, Argentina
  • Pfizer Investigational Site
    Capital Federal, C1428AQK, Argentina
  • Pfizer Investigational Site
    S2000DHL- Rosario - Santa Fe, Argentina
  • Pfizer Investigational Site
    Concord, New South Wales NSW 2139, Australia
  • Pfizer Investigational Site
    Randwick, New South Wales 2031, Australia
  • Pfizer Investigational Site
    Adelaide, South Australia 5006, Australia
  • Pfizer Investigational Site
    Ashford, South Australia 5035, Australia
  • Pfizer Investigational Site
    Dulwich, South Australia 5065, Australia
  • Pfizer Investigational Site
    Geelong, Victoria 3220, Australia
  • Pfizer Investigational Site
    Heidelberg, Victoria 3081, Australia
  • Pfizer Investigational Site
    Nedlands, Western Australia WA 6009, Australia
  • Pfizer Investigational Site
    Randwick, NSW 2031, Australia
  • Pfizer Investigational Site
    Genk, 3590, Belgium
  • Pfizer Investigational Site
    Leuven, 3000, Belgium
  • Pfizer Investigational Site
    Sao Paulo, SP 04013002, Brazil
  • Pfizer Investigational Site
    Sao Paulo, SP 04062-003, Brazil
  • Pfizer Investigational Site
    Sao Paulo, SP 04230-000, Brazil
  • Pfizer Investigational Site
    São Caetano do Sul, SP 09540-830, Brazil
  • Pfizer Investigational Site
    Calgary, Alberta T2N 2T9, Canada
  • Pfizer Investigational Site
    Calgary, Alberta T2N 4N1, Canada
  • Pfizer Investigational Site
    Vancouver, British Columbia V5Z 3A6, Canada
  • Pfizer Investigational Site
    Vancouver, British Columbia V5Z 3Y1, Canada
  • Pfizer Investigational Site
    Vancouver, British Columbia V6H 3X8, Canada
  • Pfizer Investigational Site
    Winnipeg, Manitoba R3A 1M3, Canada
  • Pfizer Investigational Site
    Hamilton, Ontario L8N 1Y2, Canada
  • Pfizer Investigational Site
    Hamilton, Ontario L8N 2B6, Canada
  • Pfizer Investigational Site
    Hamilton, Ontario L8N 4A6, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M5C 2T2, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H2X 1P1, Canada
  • Pfizer Investigational Site
    Montréal, Quebec H5B 1B2, Canada
  • Pfizer Investigational Site
    Sainte-Foy, Quebec G1V 3M7, Canada
  • Pfizer Investigational Site
    Sainte-foy, Quebec G1V 4G2, Canada
  • Pfizer Investigational Site
    Saskatoon, Saskatchewan S7K 0H6, Canada
  • Pfizer Investigational Site
    Curridabat, San Jose, Costa Rica
  • Pfizer Investigational Site
    Paseo Colon, San Jose, Costa Rica
  • Pfizer Investigational Site
    San Pedro, San Jose, Costa Rica
  • Pfizer Investigational Site
    Cartago, Costa Rica
  • Pfizer Investigational Site
    Escazu, Costa Rica
  • Pfizer Investigational Site
    San Jose, Costa Rica
  • Pfizer Investigational Site
    Zagreb, 10.000, Croatia
  • Pfizer Investigational Site
    Zagreb, 10000, Croatia
  • Pfizer Investigational Site
    Aarhus C, 8000, Denmark
  • Pfizer Investigational Site
    Hvidovre, DK-2650, Denmark
  • Pfizer Investigational Site
    Cairo, Egypt
  • Pfizer Investigational Site
    Heliopolis, Cairo, Egypt
  • Pfizer Investigational Site
    Parnu, 80010, Estonia

Showing the first 100 of 201 sites across 32 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Ensrud K, LaCroix A, Thompson JR, Thompson DD, Eastell R, Reid DM, Vukicevic S, Cauley J, Barrett-Connor E, Armstrong R, Welty F, Cummings S. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial. Circulation. 2010 Oct 26;122(17):1716-24. doi: 10.1161/CIRCULATIONAHA.109.924571. Epub 2010 Oct 11. PubMed 20937977 ↗
  • Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong RA, Thompson DD, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R; PEARL Study Investigators. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010 Feb 25;362(8):686-96. doi: 10.1056/NEJMoa0808692. Erratum In: N Engl J Med. 2011 Jan 20;364(3):290. Kucu kdeveci A [corrected to Kucukdeveci, A]. PubMed 20181970 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2001, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2005
First posted
Sep 1, 2005
Start
Nov 2001
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Results delay requested
Mar 26, 2009
Last update
Aug 15, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00141323
First posted
Sep 1, 2005
Start date
Nov 2001
Primary completion
Dec 2007
Completion
Dec 2007
Last update
Aug 15, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lasofoxifene

Start the discussion